Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9h-purin-6-ylaMine is a synthetic small molecule belonging to the class of 6-amino purines. It features a purine core substituted with butyl and benzyl groups as well as fluorine and methoxy functionalities. The compound has been described in the context of experimental research and is listed in DrugBank (DB04054) as an experimental drug[6]. While its precise mechanism of action is not fully characterized in public databases, it belongs to a family of purine-based compounds that have been investigated for their potential inhibitory activity against heat shock protein 90 (HSP90), a molecular chaperone involved in cancer cell survival pathways[7][4][5]. There are no approved therapeutic indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 9-butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9h-purin-6-ylamine.